type of report	Current report
number	63/2013
company	PHARMENA

## Qualification of PHARMENA S.A. to NCIndex30

The Management Board of PHARMENA S.A. informs that pursuant to resolution no. 452/2007 of 3<sup>rd</sup> July 2007 r. with further amendments, adopted by the Management Board of Warsaw Stock Exchange S.A. in Warsaw (GPW), after the session on 20<sup>th</sup> September 2013, the Stock Exchange will perform a quarterly revision concerning the NCIndex30 portfolio. The NCIndex30 index portfolio covers 30 the most liquid companies introduced to trading on the NewConnect market. According to the methodology of the index, the PHARMENA S.A. shares will enter the NCIndex30 portfolio after the session on 20<sup>th</sup> September 2013. This is yet another distinction for PHARMENA S.A. (together with qualifying of PHARMENA S.A. shares to the prestigious NCLead segment).

The information is made public due to the fact that the qualification of PHARMENA S.A. to NCIndex30 confirms the free float of the company's financial instruments.

Legal basis: Alternative Trading System Rules – Exhibit 3 "Current and Periodical Information in the Alternative Trading System on the NewConnect Market", Article 3 (1).

## Representatives of the company:

- Konrad Palka President of the Board
- Marzena Wieczorkowska Vice President of the Board